Highlight Therapeutics (formerly Bioncotech) is a clinical-stage immune-oncology company. It develops RNA-based therapies against validated targets in cancer and immune cells. Its drug BO-112 induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing.